已核实 DOI 相关产品: 2

Engineering Escherichia coli for the S-selective production of 2-hydroxyisovalerate

Journal 2025 · IF 4.7 · 发表于 2025 年 10 月 8 日
作者: Peiling Wu,Haofeng Chen,Guojun Yang,Haoyu Qin,Qian Zhang,Yuxin Chen,Dongjiang Lin,Yang Zhang,Shuyong Lin,Shizhen Wang,Jifeng Yuan
阅读全文 在 PubMed 查看

摘要

2-Hydroxyisovalerate (2-HIV) is a value-added chemical that is widely applied in the synthesis of bioactive compounds and polymers. Here, we report an underexplored metabolic route for the de novo production of S -type 2-HIV ( S -HIV) in Escherichia coli . In particular, we identified promiscuous activity of 4-hydroxymandelate synthase (HmaS) from Amycolatopsis orientalis towards the conversion of 2-keto-4-methyl-pentanoate (2-KMP, an immediate precursor for L-leucine) to S -HIV. Next, we designed a variant HmaS (S201F) with abolished activity for mandelate and 4-hydroxymandelate synthesis, thereby minimizing byproduct formation. Coupled with systematic optimization of the L-leucine biosynthetic pathway, we achieved de novo production of S -HIV at 8.1 mM (0.95 g/L) in shake flasks and 33.9 mM (4.0 g/L) in 2-L fed-batch fermentation. In summary, this work represents the first time to realize the efficient synthesis of S -configuration 2-HIV in metabolically engineered E. coli .

本研究中使用的阿拉丁产品

2 款产品在本文中被引用